Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Immusoft Corporation maintains a company patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 2 pending office actions. These actions are being processed by 2 distinct examiners across 2 distinct art units, which indicates a diversified examination environment.
WESTON, ALYSSA G is identified as the busiest examiner for this portfolio, with 1 pending office action under review. This means that the 2 pending office actions are split between different examiners, each handling a single case. The use of 2 distinct art units suggests that the pending matters involve different technical aspects of Biotechnology & Pharmaceuticals.
Practitioners must develop separate strategies for each of the 2 distinct examiners involved. Since the busiest examiner pending count is 1, no single individual controls the majority of the pending workload. This distribution requires the applicant to navigate the specific standards and preferences of two different art units while responding to the active office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 1 | 59.5% | +49.0% |
| REGLAS, GEORGIANA C | 1 | 39.2% | +33.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16981618 | B CELLS GENETICALLY ENGINEERED TO SECRETE FOLLISTATIN AND METHODS OF USING THE SAME TO TREAT FOLLISTATIN-RELATED DISEASES, CONDITIONS, DISORDERS AND TO ENHANCE MUSCLE GROWTH AND STRENGTH | REGLAS, GEORGIANA C | 60d overdue |
| 17886337 | B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS | WESTON, ALYSSA G | 46d overdue |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17886337 | B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS | WESTON, ALYSSA G | 1633 | Other | Final Rejection | 46d overdue | Pending | Aug 11, 2022 |
| 16981618 | B CELLS GENETICALLY ENGINEERED TO SECRETE FOLLISTATIN AND METHODS OF USING THE SAME TO TREAT FOLLISTATIN-RELATED DISEASES, CONDITIONS, DISORDERS AND TO ENHANCE MUSCLE GROWTH AND STRENGTH | REGLAS, GEORGIANA C | 1651 | §103 | Final Rejection | 60d overdue | Pending | Sep 16, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmusoft Corporation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Alyssa G Weston has the most, with 1 of Immusoft Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
